Karyopharm Therapeutics Inc.: management transactions · United States · SEC (Form 4)

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a U.S.-based biopharmaceutical company listed on the Nasdaq (United States) and headquartered in Newton, Massachusetts. Founded in 2008, the company built its scientific identity around inhibition of nuclear export, a differentiated mechanism intended to disrupt the survival and proliferation of cancer cells. Karyopharm is now a commercial-stage organization with an international footprint that includes presence in Germany and Israel, while its operational center remains in the United States. ([karyopharm.com](https://www.karyopharm.com/about/company-overview/?utm_source=openai)) The company’s business is anchored by XPOVIO® (selinexor), its flagship oral oncology therapy. XPOVIO is FDA-approved in multiple hematologic cancer settings, including multiple myeloma, and remains Karyopharm’s principal commercial asset and revenue driver. Beyond this marketed product, the company is advancing a clinical pipeline focused on high-unmet-need oncology indications, with several drug candidates in development. Karyopharm states that it has one approved product and multiple clinical-stage programs, underscoring a model that combines commercial execution with late-stage pipeline optionality. ([fda.gov](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma?utm_source=openai)) From a competitive standpoint, Karyopharm operates in highly contested oncology markets alongside larger pharmaceutical companies and specialized biotech peers. Its edge lies in its XPO1 biology and in a focused strategy targeting difficult-to-treat cancers where treatment options remain limited. That niche orientation can be attractive if clinical data translate into meaningful efficacy and tolerability advantages, but it also leaves the company exposed to regulatory risk, competitive pressure, and the financing needs typical of small-cap biotech names. ([karyopharm.com](https://www.karyopharm.com/about/?utm_source=openai)) Recent developments are especially important for the investment case. In late 2025 and early 2026, Karyopharm highlighted that top-line data from its Phase 3 SENTRY trial in myelofibrosis were expected in March 2026, while top-line results from a Phase 3 endometrial cancer study were still on track for mid-2026. The company also reported that 2025 revenue was driven largely by U.S. XPOVIO net product sales and discussed cost-reduction actions, liquidity management, and recent financing activity. For French-speaking investors, Karyopharm should be viewed as a Nasdaq-listed U.S. oncology company with a concentrated commercial base, a clinically driven near-term catalyst calendar, and meaningful upside or downside sensitivity to 2026 trial readouts. ([investors.karyopharm.com](https://investors.karyopharm.com/2026-02-12-Karyopharm-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Company-Progress?utm_source=openai))